Are you one of those families racing to find new asthma medications as respiratory virus season approaches? The Massachusetts Department of Public Health is trying to help patients and families access ...

Although bronchial hyperresponsiveness to cholinergic agents is a main feature of asthma, the role of anticholinergic drugs in chronic asthma management has been largely underestimated.

A common inhaler drug used to treat tens of thousands of British asthma sufferers has been linked to a rare and potentially fatal hormone condition in children. New research, funded by the ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

A NEW clinical trial has found that the asthma drug montelukast does not shorten the duration of symptoms for ...

DelveInsight's 'Severe Asthma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline severe asthma ...

It has previously modelled peak sales for the new drug of around £3 billion a year. A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early after ...

Asthma is associated with memory problems in children, a new study has found. Further, the early onset of asthma might worsen ...

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics ...

“Childhood is a period of rapid improvement in memory and, more generally, cognition. In children with asthma that ...

Opens in a new tab or window Among patients with mild to moderate COVID-19, the asthma drug montelukast (Singulair) did not reduce duration of symptoms, results of the randomized controlled ACTIV ...